GSK3 suppression upregulates β-catenin and c-Myc to abrogate KRas-dependent tumors

Mutant KRas is a significant driver of human oncogenesis and confers resistance to therapy, underscoring the need to develop approaches that disable mutant KRas-driven tumors. Because targeting KRas directly has proven difficult, identifying vulnerabilities specific for mutant KRas tumors is an impo...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Nat Commun
Hlavní autoři: Kazi, Aslamuzzaman, Xiang, Shengyan, Yang, Hua, Delitto, Daniel, Trevino, José, Jiang, Rays H. Y., Ayaz, Muhammad, Lawrence, Harshani R., Kennedy, Perry, Sebti, Saïd M.
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group UK 2018
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6279809/
https://ncbi.nlm.nih.gov/pubmed/30514931
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-018-07644-6
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky